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Abstract
Many molecular and cellular abnormalities detected in the diabetic retina support a role for IL-1b-driven neuroinflammation
in the pathogenesis of diabetic retinopathy. IL-1b is well known for its role in the induction and, through autostimulation,
amplification of neuroinflammation. Upregulation of IL-1b has been consistently detected in the diabetic retina; however,
the mechanisms and cellular source of IL-1b overexpression are poorly understood. The aim of this study was to investigate
the effect of high glucose and IL-1b itself on IL-1b expression in microglial, macroglial (astrocytes and Mu ¨ller cells) and
retinal vascular endothelial cells; and to study the effect of diabetes on the expression of IL-1b in isolated retinal vessels and
on the temporal pattern of IL-1b upregulation and glial reactivity in the retina of streptozotocin-diabetic rats. IL-1b was
quantified by RealTime RT-PCR and ELISA, glial fibrillar acidic protein, a2-macroglobulin, and ceruloplasmin by
immunoblotting. We found that high glucose induced a 3-fold increase of IL-1b expression in retinal endothelial cells
but not in macroglia and microglia. IL-1b induced its own synthesis in endothelial and macroglial cells but not in microglia.
In retinal endothelial cells, the high glucose-induced IL-1b overexpression was prevented by calphostin C, a protein kinase C
inhibitor. The retinal vessels of diabetic rats showed increased IL-1b expression as compared to non-diabetic rats. Retinal
expression of IL-1b increased early after the induction of diabetes, continued to increase with progression of the disease,
and was temporally associated with upregulation of markers of glial activation. These findings point to hyperglycemia as the
trigger and to the endothelium as the origin of the initial retinal upregulation of IL-1b in diabetes; and to IL-1b itself, via
autostimulation in endothelial and macroglial cells, as the mechanism of sustained IL-1b overexpression. Interrupting the
vicious circle triggered by IL-1b autostimulation could limit the progression of diabetic retinopathy.
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Introduction
Despite the improvements in the management of hyperglycemia
and hypertension, most adult with diabetes do not achieve the
target levels of glycemic and blood pressure control [1,2]. For
these reasons, diabetic retinopathy remains a prevalent complica-
tion of diabetes and a leading cause of vision loss and blindness in
the adult population [3]. In order to develop effective treatments
to prevent vision loss in diabetes, there is a need for a better
understanding of the mechanisms linking the diabetic milieu to
retinal damage.
Growing evidence suggest that IL-1b-driven neuroinflammation
could be one such mechanism. Although diabetic retinopathy does
not have the characteristics of an overt inflammatory reaction,
features of neuroinflammation are present in the diabetic retina
[4]. These include macroglial and microglial activation, leukos-
tasis, increased vascular permeability, and increased expression of
cytokines, acute phase proteins, and vasoactive peptides [5–11].
IL-1b is a multifunctional proinflammatory cytokine [12] and
the main trigger of the neuroinflammatory cascade [13]. Release
of IL-1b is one of the earliest events after traumatic and ischemic
brain injures as well as in chronic neurodegenerative diseases.
Once released, IL-1b elicits a multitude of effects on target cells
that lead to and modulate the inflammatory response and tissue
damage [13]. By inducing its own synthesis via autocrine/
paracrine autostimulation IL-1b is not only a trigger but also an
amplifier of inflammation [14–18].
Several observations support a role for IL-1b as a probable
mediator of retinal damage in diabetes. IL-1b is increased in the
retina in experimental diabetes [7,10,19,20], and such increase is
due to increased retinal synthesis [10]. Interleukin converting
enzyme/caspase-1, the enzyme responsible for the production of
biological active IL-1b [12], is activated in the retina in both
human and experimental diabetic retinopathy [21,22]. Intercellu-
lar adhesion molecule-1, the transcription factors CEBP-b and -d,
and other IL-1b-dependent genes are upregulated in the diabetic
retina [10,23]. Mice lacking IL-1 receptor I are protected from the
development of acellular capillaries in diabetes [22].
Monocytes, aortic and retinal endothelial cells, and retinal
Mu ¨ller cells have been reported to upregulate and/or secrete
increased amount of IL-1b when exposed to high glucose in vitro
[24–28]. Although these findings point to vascular endothelial cells
and Mu ¨ller cells as a possible source of increased IL-1b in the
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cells overexpress IL-1b in diabetes. Moreover, the contribution of
microglial cells and astrocytes as a source of IL-1b and the
mechanism of IL-1b upregulation in the diabetic retina remain
unknown.
To identify the cellular source and mechanism of the diabetes-
induced upregulation of IL-1b in the retina we studied the effect of
high glucose and IL-1b itself on the expression of the cytokine in
microglial, macroglial, and retinal vascular endothelial cells; and
the effect of diabetes on the expression of IL-1b in isolated retinal
vessels and on the temporal pattern of IL-1b upregulation and glial
reactivity in the retina of streptozotocin-diabetic rats.
Methods
Ethical Statement
All procedures involving animals conformed to the Association
for Research in Vision and Ophthalmology resolution on the use
of animals in research and were approved by the Animal Use and
Care Committee of the Schepens Eye Research Institute
(Protocols # S-163-0309 and S-189-0411).
Cell isolation and culture
Rat microglial cells (RMG) and astrocytes (RA) were isolated
from 1–3 days old Wistar rats as described by Tham et al. [29] and
Ramsauer et al. [30] respectively. Cerebral cortices were
dissociated by repeated pipetting in ice-cold calcium-free Hanks
balanced saline solution and filtered through a 100 mm nylon
mesh. The dissociated cells were pelleted by centrifugation at
1400 rpm for 5 min, resuspended in 10% FBS-DMEM, and
plated on poly-L-lysine-coated tissue flasks. The medium was
replaced on days 3, 5 and 9 after plating. For isolation of RMG, at
day 13 the flasks were shaken at 100 rpm for 2 h at 37uC. The
supernatant was collected and the detached microglial cells were
pelleted by centrifugation at 3506g for 5 min, resuspended in
10% FBS-DMEM, and plated on poly-L-lysine-coated dishes. For
isolation of RA, at day 10 the flasks were shaken at 200 rpm at
37uC for 2 days and at 100 rpm for 2 additional days. After
washing with PBS, the adherent cell monolayers were trypsinized
and the cells plated on poly-L-lysine coated dishes and cultured in
10% FBS-DMEM. Purity of primary isolates and subcultures was
assessed by CD11b immunostaining and isolectin B4 binding for
microglia and glial fibrillary acidic protein (GFAP) immunostain-
ing for astrocytes (Fig. S1). Rat retinal Mu ¨ller cells (RMC) were
isolated from 6 days old Wistar rats (Taconic Farms, Hudson, NY)
as described by Hicks et al. [31]. After an overnight at room
temperature in the dark in DMEM (Gibco, Life Technologies,
Carlsbad, CA) the enucleated eyes were incubated at 37uC for
30 min in the same medium supplemented with 0.1% trypsin and
70 U/ml collagenase (Sigma, St. Louis, MO). The retinas were
dissected, dissociated by repeated pipetting, and cultured in
DMEM supplemented with 10% FBS for 6 days before the first
medium change. Purity of primary isolates and subcultures was
assessed by vimentin and glutamine synthetase immunostaining
(Fig. S1). Bovine retina endothelial cells (BREC) were isolated and
cultured using procedures optimized to prevent pericyte contam-
ination as previously described [32]. For this purpose, the primary
cultures were subjected to brief trypsinization (90 s at room
temperature) and the detached cells were replated on fibronectin-
coated dishes and cultured in endothelial growth medium (EBM
supplemented with bovine brain extract 1:1000, Lonza, Walkers-
ville, MD) containing 10% horse serum from platelet-poor plasma
(Sigma) [32]. Purity of primary isolates and subcultures was
assessed by von Willebrand factor immunostaining (Fig. S1).
Experiments with RMG were performed with freshly isolated
primary cells, those with RA and RMC with cells at passage 2 to 5,
and those with BREC with cells at passage 4 to 7. All cells were
maintained at 37uC in 5% CO2, 95% air, and media were
changed every 2 days. To study the effect of high glucose, cells
were exposed to either normal glucose (5.5 mM, NG) or high
glucose (25 mM, HG) concentrations for 4 days. Cell cultured in
equimolar mannitol and, in some experiments, L-glucose were
used as control for the effects of hypertonicity. To study the effect
of PKC activation, BREC, grown to confluency in NG medium,
were stimulated with 10 and 30 nM phorbol 12 myristate 13-
acetate (PMA, Sigma) for 4 hours before harvesting [33]. For the
PKC inhibition experiments, BREC were cultured for 4 days in
NG, HG, and HG containing the non-selective PKC inhibitor
calphostin C (50 nM, EMD-Calbiochem, Gibbstown, NJ). To test
for the effect of IL-1b autostimulation, cells were cultured in NG
until confluency and then incubated in serum-free NG medium for
1 day before stimulation with recombinant IL-1b (10 ng/ml
medium) for 4 hours. Bovine IL-1b (Thermo Scientific, Rockford,
IL) was used in the experiments with BREC, human recombinant
IL-1b (R&D, Minneapolis, MN) was used in the experiments with
RMC, RA, and RMG. In some experiments, RMG pre-incubated
in serum-free medium as above, were stimulated with LPS at
1 mg/ml medium (from E. Coli, Sigma).
Animals
Sprague-Dawley male rats (5 weeks of age; Taconic Farms) were
randomly assigned to a diabetic and a control group. Induction of
diabetes with streptozotocin (55 mg/kg body weight) and treat-
ment of diabetic rats with maintenance insulin were as described
[10]. Diabetic rats and age-matched non-diabetic control rats were
studied at different time points from the induction of diabetes
(from 1.5 to 5 months). Rats assigned to quantification of IL1b –
RNA and protein (ELISA) – were killed by CO2 inhalation, the
eyes immediately removed and the retinas dissected and processed
for the isolation of whole retina RNA and proteins or for the
isolation of retinal vessels. To avoid artifact due to plasma a2-
macroglobulin and ceruloplasmin, rats assigned to the isolation of
retinal proteins for western blotting were perfused through the left
ventricle with phosphate buffered saline under deep anesthesia as
previously described [10]. To assess the severity of diabetes, blood
was collected at the time of death by cardiac puncture for the
measurement of glycated hemoglobin (A1C) as previously de-
scribed [10]. For the group with the shorter duration of diabetes
(1.5 months) severity of diabetes was assessed by measuring blood
glucose levels. The characteristics of the diabetic and control rats
are summarized in table 1.
Table 1. Characteristics of study rats.
Study
duration group n
body
weight (g)
glycemia
(mg/dl) A1C (%)
1.5 months diabetes 8 308620* 6336138* —
control 8 492642 2066100 —
2.5–3 months diabetes 19 382630* — 15.762.6*
control 19 561669 — 5.861.0
4.5–5 months diabetes 27 401671* — 16.061.8*
control 27 605663 — 6.161.0
*P,0.0001 vs control.
doi:10.1371/journal.pone.0036949.t001
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Rat retinal vessels were isolated by hypotonic lysis of the fresh
retina as previously described [34,35]. As previously documented,
this method yields the retinal vascular network free of glia and
neural contamination [35].
RNA isolation and RealTime RT-PCR analysis
Total RNA from cultured cells, whole retinas, and retinal
vessels, was isolated using the RNeasy mini kit (Qiagen, Valencia,
CA) following the on-column DNase digestion protocol [34].
Relative expression of IL-1b and IL1R1 in cultured cells, IL-1b in
retinal vessels, and IL-1b, IL-6, and TNF-a in whole retinas was
determined by RealTime RT-PCR using the comparative DDCt
method as described [10,34]. Primers and probe sets for bovine
IL-1b and b-actin are listed in Table S1, those for rat IL-1b,
IL1R1, IL-6, TNF-a, and b-actin were from Applied Biosystems
(Life Technologies, Carlsbad, CA).
Immunoblotting and ELISA
Preparation of retinal protein lysates and immunoblotting for
a2-macroglobulin, ceruloplasmin, GFAP, and b-actin were
performed as described [10,23,34]. IL-1b protein levels were
quantified by colorimetric sandwich ELISA (Rat IL1b Quantikine,
R&D Systems, Minneapolis, MN). Each samples was assayed in
duplicate using 50 mg of total protein per well.
Statistical Analysis
Data are summarized as means 6 SD and analyzed by
unpaired Student’s t test for two groups comparison or ANOVA
followed by Fisher’s protected least significant differences test for
multiple groups comparisons. Analysis of the PMA dose response
effect (p for trend) was performed by linear regression using IL-1b
as the dependent variable and the PMA concentration as the
independent variable. Statistical analysis was performed with
StatView 5.0 (SAS Institute, Cary, NC). A P value#0.05 was
considered as evidence of a statistically significant difference
between groups.
Results
HG induces IL-1b expression in retinal vascular
endothelial cells but not in Mu ¨ller cells, astrocytes, or
microglia
Retinal vascular endothelial and Mu ¨ller cells have been shown
to upregulate IL-1b when exposed to high glucose concentration.
To test whether high glucose has a similar effect also on astrocytes
and microglia, we compared IL-1b expression in BREC, RMC,
RA, and RMG exposed to NG and HG. Under basal culture
conditions (NG), IL-1b mRNA was detected in all four cell types
examined. Exposure to HG for 4 days resulted in a significant
upregulation of IL-1b in BREC (3 fold increase vs NG, P=0.0001)
(Fig. 1). The levels of IL1b expression in BREC exposed to
equimolar mannitol or L-glucose were not different from those in
control cells (NG), excluding increased osmolarity as the cause of
the changes induced by HG. At difference with BREC, there was
no effect of HG on IL-1b expression in Mu ¨ller cells, astrocytes,
and microglia neither after 4 days (Fig. 1) nor after longer
exposure (7 days, not shown).
Inhibition of PKC prevents the HG-induced upregulation
of IL-1b in BREC
Upregulation of IL-1b in both aortic and retinal endothelial
cells has been described, but the mechanisms underlying the effect
of HG are not known. In monocytes, protein kinase C (PKC)
activation is sufficient to induce IL-1b expression [36] and
upregulation of IL-1b by HG has been reported to occur via
a PKC-dependent mechanism [24]. Thus, we studied whether
PKC activation is sufficient to induce IL-1b expression in retinal
endothelial cells, and whether this mediates the effect of HG on
IL-1b expression in these cells. Stimulation of BREC with PMA
led to a significant, dose-dependent upregulation of IL-1b (Fig. 2A).
The degree of IL-1b induction by PMA (relative expression:
3.062.6 PMA 10 nM and 5.766.1 PMA 30 nM vs 1.060.2 in
control), albeit variable among different isolates, was comparable
to that of HG. Addition of calphostin C, a non-selective PKC
inhibitor, to BREC cultured in HG prevented the HG-induced
upregulation of IL-1b (relative expression: 1.661.1 in HG+cal-
phostin C vs 4.163 in HG, P=0.04, and 1.060.01 in NG,
P=0.6. HG vs NG, P=0.014) (Fig. 2B). At the concentration
used, calphostin C had no effect on cell viability and morphology
(Fig. S2).
IL-1b is upregulated in retinal vessels of diabetic rats
The finding that of the different cell types tested only retinal
microvascular endothelial cells upregulated IL-1b when cultured
in HG pointed to the retinal vascular endothelium as a primary
source of IL-1b in diabetes. To test whether the retinal vessels are
a source of IL-1b we examined IL-1b expression in isolated retinal
vessels of diabetic rats and age-matched control rats. As shown in
figure 3, IL-1b mRNA levels are significantly increased in the
retinal vessels of diabetic rats as compared to control rat (2.5 fold
vs NG, P=0.035).
IL-1b induces its own synthesis in BREC, Mu ¨ller cells, and
astrocytes; but not in microglia
IL-1b is known to induce its own synthesis via autocrine and
paracrine autostimulation, a mechanism that magnifies upregula-
Figure 1. Effect of high glucose on IL-1b expression in retinal
endothelial, macroglial, and microglial cells. Confluent culture of
bovine retinal vascular endothelial cells (BREC), rat Mu ¨ller cells (RMC),
astrocytes (RA), and microglia (RMG) were exposed to normal glucose
(5.5 mM, NG) or high glucose (25 mM glucose, HG) for 4 days.
Equimolar mannitol (M) and L-glucose (L-G) (BREC only) were used as
osmolar control. Total RNA was extracted and IL-1b mRNA levels were
assayed by quantitative RealTime RT-PCR. Relative expression of IL-1b
mRNA was calculated by the comparative CT method using b-actin as
endogenous control (DDCT method). Bars represent mean 6 SD of the
results obtained in independent experiments form 5 isolates of BREC
(each tested in multiple experiments comparing NG, HG, and M. L-G
was tested in three experiments, each using a different isolate), and 3
isolates of RMC, RA, and RMG. BREC: NG, HG, and M, n=14, L-G, n=3;
RMC: NG, HG, and M, n=4; RA: NG and HG, n=5, M n=2; RMG: NG and
HG, n=4, M n=2.
doi:10.1371/journal.pone.0036949.g001
IL-1b in Retinopathy Effect of Glucose and IL-1b
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36949tion of IL-1b expression. To test whether such mechanism could
be operative in the diabetic retina, we measured the expression of
IL-1b in BREC, RMC, RA, and RMG after stimulation with
recombinant IL-1b. Treatment with IL-1b led to a significant
upregulation of IL-1b in BREC (400 fold increase vs untreated,
P=0.003), Mu ¨ller cells (900 fold increase vs untreated, P=0.05),
and astrocytes (7 fold increase vs untreated control, P=0.024), but
not in microglia (Fig. 4A). Because microglial cells failed to
upregulate IL-1b in response to both high glucose and exogenous
IL-1b, we used LPS to test the responsiveness of the cells to IL-1b-
inducing stimuli. As shown in figure 4B, treatment with LPS led to
a significant upregulation of IL-1b in the isolated microglia (26
fold increase vs untreated, P,0.0001). To determine whether the
levels of expression of the IL-1b receptor could account for the
different response of macroglial and microglial cells to IL-1b
autostimulation, we compared the basal expression of IL1R1 in
the different glial cell types. As shown in Fig. 5A although IL1R1
was detectable by quantitative RT-PCR in both microglia and
macroglia, the levels of expression were $100 fold lower in
microglial cells than in Mu ¨ller cells or astrocytes. Pre-incubation of
microglial cells in serum-free medium did not alter the expression
of IL1R1 (Fig. 5B).
Upregulation of IL-1b in the diabetic retina is associated
temporally and quantitatively with glial activation
To learn about the possible relevance of IL-1b autostimulation
in the diabetic retina in vivo, we studied the time course of IL-1b
expression and its temporal relationship with the development of
glial reactivity. IL-1b is a known inducer of glial activation. In the
rat retina, IL-1b expression began to increase between 1.5 and 2.5
months after the onset of diabetes and continued to increase at
later time points (Fig. 6A). At variance with IL-1b, the retinal
expression of IL-6 and TNF-a was not changed in diabetes at any
of the time points tested (Fig. S3). The increased transcription of
IL-1b in the diabetic retina was associated with increased synthesis
of the protein (6 fold vs control, P=0.0007) (Fig. 6B). The time
course of GFAP, a2-macroglobulin, and ceruloplasmin over-
expression in the retina of diabetic rats was similar to that of IL-1b
(Fig. 6C and 6D) with no changes as compared to control rats at
1.5 months from the induction of diabetes and a significant
upregulation after 3 months of diabetes.
Discussion
Our findings point to IL-1b as a trigger and propagator of
retinal neuroinflammation in diabetes. This dual role of IL-1b is
suggested by the in vitro observations that high glucose induces IL-
1b in retinal vascular endothelial cells and IL-1b induces its own
synthesis in retinal vascular endothelial cells, Mu ¨ller cells, and
astrocytes, combined with the in vivo observation that IL-1b
upregulation in the diabetic retina increases progressively in
relation to the duration of diabetes. Based on these data, we
envision a scenario in which retinal upregulation of IL-1b in
diabetes initiates in the vascular endothelium as a direct effect of
hyperglycemia, and the secreted IL-1b stimulates in an autocrine
and paracrine manner endothelial and macroglia cells, which
respond not only with signs of activation but also with enhanced
synthesis of IL-1b, thereby magnifying the features of neuroin-
flammation.
The high glucose-induced upregulation of IL-1b mRNA in
retinal vascular endothelial cells is consistent with the observation
by Kowluru et al of increased IL-1b protein levels in BREC
exposed to high glucose [26]. However, Busik et al did not observe
any effect of high glucose on the activation of ICE/caspase-1 and
secretion of IL-1b in HREC [28]. Although this finding indicates
that high glucose alone is not sufficient to increase processing and
Figure 2. Effects of PKC inhibition on HG-induced IL-1b upregulation in BREC. (A) Effect of PKC activation on IL-1b expression. Confluent
cultures of BREC (NG medium) were stimulated with PMA (10 and 30 nM) for 4 hours. Total RNA was extracted and IL-1b mRNA levels were assayed
by quantitative RealTime RT-PCR. Bars represent mean 6 SD of the results obtained in three different isolates tested in independent experiments.
n=9/group (B) Confluent cultures of BREC were exposed to NG, HG, or HG in the presence of the non-selective PKC inhibitors calphostin C (CalC,
50 mM) for 4 days. Total RNA was extracted and IL-1b mRNA levels were assayed by quantitative RealTime RT-PCR. Bars represent mean 6 SD of the
results obtained in three different isolates tested in independent experiments. n=6/group.
doi:10.1371/journal.pone.0036949.g002
Figure 3. Upregulation of IL-1b in retinal vessels in diabetes.
Retinal vessels were isolated by hypotonic lysis from diabetic rats (D, 5
months of diabetes duration) and age-matched control rats (C). IL-1b
mRNA levels were quantified by RealTime RT-PCR. Bars represent mean
6 SD of the results obtained in the indicated number of rats.
doi:10.1371/journal.pone.0036949.g003
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those authors and, thus, an effect of high glucose on IL-1b
synthesis in HREC could not be excluded. Our finding of
increased IL-1b expression in rat retinal vessels in diabetes
indicates that retinal vascular cells are a source of IL-1b in vivo.
While the analysis of isolated retinal vessels does not permit to
discriminate between endothelial cells and pericytes/vascular
smooth muscle cells as the source of IL-1b, the HG-induced
upregulation of the cytokine in cultured endothelial cells proposes
vascular endothelium as a cellular source of IL-1b overexpression
in response to hyperglycemia.
The mechanisms of IL-1b induction in response to bacterial
endotoxins or IL-1b itself are well characterized [37], but the
signaling pathways linking high glucose to IL-1b upregulation are
still poorly understood. The only available data are from studies of
monocytes demonstrating that the induction of IL-1b by high
glucose is mediated in these cells by a PKCa-dependent activation
of p38MAPK, ERK, and NF-kB [24]. PKC activation has been
shown to occur in retinal endothelial cells exposed to high glucose
[38] as well as in the diabetic retina [39,40], and has been
proposed as a mechanism underlying endothelial dysfunction in
diabetes. Our findings of IL-1b upregulation by the PKC agonist
PMA and prevention of the HG-induced IL-1b upregulation in
BREC by calphostin C point to upregulation of IL-1b as
a potential link between PKC activation and vascular dysfunction
in diabetes.
In contrast to the effect on BREC, high glucose did not lead to
upregulation of IL-1b in microglia and macroglia. In cerebral
Figure 4. IL-1b autostimulation in retinal endothelial, macroglial, and microglial cells. (A) Effect of IL-1b on IL-1b expression. Confluent
culture of BREC, RMC, RA, and RMG were pre-incubated in serum-free medium for 24 hours before stimulation with rIL-1b (bovine rIL-1b for BREC;
human rIL-1b for RMC, RA and RMG) at 10 ng/ml of medium. Cells were harvested after 4 hours and IL-1b mRNA levels were assayed by quantitative
RealTime RT-PCR. Bars represent mean 6 SD of the results obtained from different isolates of each cell type. BREC, RMC, and RA: n=3, RMG: n=4. (B)
Effect of LPS on IL-1b expression in microglia. RMG confluent cultures were pre-incubated in serum-free medium for 24 hours before stimulation with
LPS at 1 mg/ml of medium for 4 hours. The expression of IL-1b was determined by RealTime RT-PCR. Bars represent mean 6 SD of the results
obtained from two isolates.
doi:10.1371/journal.pone.0036949.g004
Figure 5. Differential expression of IL1R1 in rat microglial and macroglial cells. (A) Rat microglia (RGM), Mu ¨ller cells (RMC), and astrocytes
(RA) were cultured in NG medium for 4 days. Total RNA was extracted and IL1R1 mRNA levels were assayed by quantitative RealTime RT-PCR. IL1R1
expression in Mu ¨ller cells and astrocytes was calculated relative to the expression in microglia by the comparative DDCT method using the mean DCT
obtained in microglial cells as the calibrator. Bars represent mean 6 SD of the results obtained from 2–3 isolates per cell type. RMG: n=6, RMC: n=2,
RA: n=6. (B) IL1R1 expression in microglia cultured in serum-free medium. RMG, cultured in normal medium (10% FBS) (S) until confluency, were
switched to serum-free medium (SF) for 24 hours before harvesting. Cells cultured in basal medium for the duration of the experiment were used as
control. The expression of IL1R1 was determined by RealTime RT-PCR. Bars represent mean 6 SD of the results obtained in three different isolates
tested in independent experiments. n=5/group.
doi:10.1371/journal.pone.0036949.g005
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a primary source of IL-1b [41], but extensive evidence indicates
that the initial cellular source of IL-1b in response to CNS injuries
is activated microglia with subsequent upregulation of the cytokine
in macroglia [13]. In the diabetic retina, microglia activation
precedes the occurrence of neuronal death [7] and high glucose
has been shown to induce IL-1b expression in monocytes [24].
These observations would suggest that microglial cells could
contribute to the hyperglycemia-induced upregulation of IL-1b.
However, our data, showing that high glucose is not sufficient to
induce IL-1b overexpression in microglial cells, are against this
hypothesis. One caveat in interpreting these results is that we
performed the study using brain-derived microglial cells and, thus,
we cannot exclude a direct effect of high glucose on IL-1b
expression that is specific to the retinal microglia.
As in microglial cells, high glucose had no effect on IL-1b
expression in astrocytes and in Mu ¨ller cells. The latter finding is at
variance with previous reports of increased secretion of IL-1b by
retinal Mu ¨ller cells exposed to high glucose [26,27]. Although an
effect of high glucose on IL-1b expression has not been previously
studied in astrocytes, increased secretion of IL-1b has been
described for retinal Mu ¨ller cells [27,28]. A possible explanation
for the discrepancy between our finding and those reports is that
we measured IL-1b mRNA levels after a prolonged exposure to
high glucose, whereas previous studies measured IL-1b protein
secretion after a short exposure to high glucose. Under such
circumstances, high glucose could have accelerated the processing
of a pre-existing pool of pro-IL1b without changes in gene
expression. Indeed, processing of pro-IL-1b followed by secretion
of the mature protein has been proposed as the mechanism for the
rapid release of IL-1b independent of de novo protein synthesis
following traumatic brain injuries [42].
IL-1b can induce his own synthesis in an autocrine and
paracrine fashion, a mechanism that is thought to propagate and
amplify the inflammatory response [43]. Indeed, IL-1b-induced
IL-1b synthesis has been previously described in human macro-
vascular endothelial cells [14] and other cell types [15–18]. In this
study, we found that IL-1b induces IL-1b expression also in retinal
microvascular endothelial cells, Mu ¨ller cells, and, albeit to a lesser
extent, astrocytes. The IL-1b-mediated induction of IL-1b
observed in BREC and Mu ¨ller cells suggests that the glucose-
mediated increase of IL-1b in retinal endothelial cells might lead
to further increase of IL-1b in the diabetic retina by autocrine and
paracrine self-amplification of IL-1b expression in endothelial and
macroglial cells. The occurrence of an IL-1b-driven IL-1b
overexpression in the diabetic retina is supported by the pro-
gressive, disease duration-dependent increase of IL-1b mRNA –
from 1.6 fold at 2.5 months and 2.5 fold at 4.5 months in this
study, to 10 folds at 6 months of diabetes in our previous study
[10]– a temporal pattern of IL-1b upregulation consistent with
a positive feed-back effect of IL-1b itself.
At variance with the observation in endothelial and macroglial
cells, we did not find evidence of IL-1b autostimulation in
microglia. In neuroinflammation, activated microglia is recognized
as the major cellular source of IL-1b. However, whether microglial
cells are a target of the cytokine and whether IL-1b induces its own
Figure 6. Effect of diabetes duration on the retinal expression of IL-1b and markers of glial reactivity. All experiments were conducted
in diabetic (D) and age-matched control (C) rats. (A) Time course of IL-1b upregulation in relation to diabetes duration. IL-1b mRNA levels in the retina
were quantified by RealTime RT-PCR. Bars represent mean 6 SD of the results obtained in the indicated number of rats at each time point tested. (B)
Increased protein levels of IL-1b protein in the retina in diabetes. IL-1b protein was quantified by ELISA at 5 months of diabetes duration. Bars
represent mean 6 SD of the results obtained in the indicated number of rats. (C) Time course of GFAP, a2-macroglobulin (a2M), and ceruloplasmin
(Cp) expression. Protein levels were quantified by western blot analysis of whole retina lysates. Data are expressed as densitometric units per mgo f
protein. Bars represent mean 6 SD. n=4 rats/group at 1.5 months and 9 rats/group at 3 months. (D) Representative Western blots of GFAP, a2M, and
Cp at 3 months of diabetes duration. b-actin was used as control for gel loading.
doi:10.1371/journal.pone.0036949.g006
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to induce its own synthesis in human fetal microglial cells [45] but
not in mouse neonatal microglia [46]. We have now found that,
similarly to mouse microglia, rat microglial cells do not upregulate
IL-1b in response to IL-1b, but do so when stimulated with LPS.
Since IL1R1 and TLR4 – the LPS receptor – share the same
downstream signaling molecules [47], IL-1b induction by LPS
indicates that the IL1R1/TLR signaling pathway is functional in
these cells and that the failure of IL-1b to induce IL-1b in rat
microglia is most likely due to the low expression of IL1R1.
IL-1b induces gliosis in vivo [48] and, in vitro, stimulation of
astrocytes with IL-1b leads to upregulation or de-novo synthesis of
several of the genes known to be regulated in reactive glia [49].
Glial reactivity is a key component of neuroinflammation and
retinal glial reactivity is a well documented early feature of both
human and experimental diabetic retinopathy [5,6]. Our previous
investigation of the reactive phenotype of Mu ¨ller cell in rats with 6
months of diabetes identified the upregulation/induction of a2-
macroglobulin, ceruloplasmin, and other acute-phase proteins as
a major component of Mu ¨ller cells reactivity [10]. The upregula-
tion of acute-phase proteins was associated with retinal upregula-
tion of IL-1b, but not of TNF-a or IL-6 [10]. In this study, we
observed that the retinal expression of GFAP and acute-phase
proteins increases in relation to diabetes duration with a pattern
similar to that of IL-1b upregulation. Similar to our previous study
of rats with longer disease duration, we did not find changes in the
retinal expression of TNF-a, which is in contrast with other reports
in the literature. However, in two of those other reports [50,7], the
observation of increased retinal TNF-a in response to diabetes was
made after 1 or 2 weeks of diabetes and such increase could have
been secondary to the initial acute metabolic imbalance after the
induction of diabetes or to streptozotocin toxicity. In other two
reports [51,52], the increase in TNF-a was found in rats with
durations of diabetes similar to those of our studies. One possible
explanation for the discrepancy between those results and ours is
the treatment of diabetic rats. To prevent weight loss and permit
weight gain while maintaining hyperglycemia, the animals in our
studies were treated with small doses of insulin from the onset of
diabetes, whereas it appears that the animals in those other studies
were not insulin treated. While our finding does not prove
causality between upregulation of IL-1b and macroglial activation,
the temporal association between upregulation of acute-phase
proteins and IL-1b without changes of IL-6 and TNF-a proposes
IL-1b as a candidate mediator of glial activation in the diabetic
retina.
In summary, our findings point to hyperglycemia as the trigger
and to the vascular endothelium as the origin of the initial increase
of IL-1b expression in the diabetic retina, and to IL-1b itself, via
autocrine/paracrine autostimulation in endothelial and glial cells,
as the mechanism of sustained retinal upregulation of this
cytokine. Because of the role that IL-1b can have in the
development of retinal glial activation and endothelial dysfunction
in diabetes, interrupting the vicious circle triggered by IL-1b
autostimulation could be a mechanism to limit the progression of
diabetic retinopathy.
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